Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 80-85

  Horie, Shuichi ^a   Hiraishi, Sayuri ^a   Hamuro, Tsutomu ^a   Kamikubo, Yu Ichi ^a   Matsuda, Juzo ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Factor Xa generation; Heparin; Oxidized low density lipoprotein; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10; HEPARIN; LOW DENSITY LIPOPROTEIN; PEPTIDE; PROTEINASE INHIBITOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

AGAR GEL ELECTROPHORESIS; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BINDING KINETICS; BLOOD CLOTTING PARAMETERS; CARBOXY TERMINAL SEQUENCE; DRUG BINDING; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN;

EID: 0036149557     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612947     Document Type: Article

References (29)

1. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
2. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component
3. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
4. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
5. Regulation of coagulation by a multivalent Kunitz-type inhibitor
6. Characterization of the inhibitory of tissue factor in serum
7. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
8. Purification and characterization of the lipoprotein-associated coagulatioin inhibitor from human plasma
9. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
10. The pathogenesis of atherosclerosis: A perspective for the 1990s
11. Roles of oxidized low-density lipoprotein in atherogenesis
12. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
13. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells
14. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation
15. Oxidized low-density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes
16. Coronary thrombosis
17. Identification of active tissue factor in human in coronary atheroma
18. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation
19. Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation
20. Oxidized low-density lipoprotein impairs the anticoagulant function of tissue factor pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells
21. Effect of heparin on the inhibitor of factor Xa by tissue factor pathway inhibitor: A segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site
22. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma
23. A method for systematic purification from bovine plasma of six vitamin K-dependent coagulation factors: Prothrombin, factor X, factor IX, protein S, protein C, and protein Z
24. Electrophoretic mobility changes in oxidized human low-density lipoprotein measured by laser Doppler electrophoresis
25. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor
26. Tissue factor pathway inhibitor: Proposed heparin recognition region
27. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins
28. Heterogeneity of plasma tissue factor pathway inhibitor
29. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)